American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MYLOX-1: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor, GB2064, in myelofibrosis
    Meeting Abstract

    Verstovsek, S.; Mascarenhas, J.; Rampal, R. K.; Cilloni, D.; Harrison, C.; Jacoby, B.; Slack, R. J.; Aslanis, V.; Singh, B.; Lindmark, B.
    Blood (2022)

    Fulltext@MSK | Save
  • Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP)-H. Jean Khoury Cure CML Consortium study
    Meeting Abstract

    Atallah, E. L.; Visotcky, A.; Flynn, K. E.; Zhang, M. J.; Radich, J. P.; Yang, J.; Oehler, V. G.; Tantravahi, S. K.; Smith, B. D. D.; Ibarz, J. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term molecular testing and clinical response of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: 5-year follow-up from SIMPLICITY, a prospective, observational study
    Meeting Abstract

    Cortes, J. E.; Goldberg, S. L.; Paquette, R.; Williams, L. A.; Hehlmann, R.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D. R.; DeGutis, I. S.; McBride, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119
    Meeting Abstract

    Bar-Natan, M.; Mascarenhas, J.; Gerds, A. T.; Mesa, R.; Gupta, V.; Kremyanskaya, M.; Dougherty, M.; Fabris, F.; Johnson, K.; Yu, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Impact on tumour treatment and outcome of SARS-CoV-2 infection in 91 patients with primary CNS lymphoma: A real-life study of the international PCNSL Collaborative Group
    Meeting Abstract

    Calimeri, T.; Steffanoni, S.; Laurenge, A.; Fox, C. P.; Soussain, C.; Grommes, C.; Tisi, M. C.; Boot, J.; Crosbie, N.; Visco, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Piotrowski, A.; Pentsova, E.; Gavrilovic, I.; Stone, J. B.; Lin, A.; Wongchai, V.; Madzsar, J. T.; Malani, R.; Nolan, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status
    Meeting Abstract

    Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
    Blood (2022)

    Fulltext@MSK | Save
  • Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling
    Meeting Abstract

    Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant
    Meeting Abstract

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save